Intensive Urate-Lowering May Protect Kidneys in Type 2 Diabetes
The effects of combined verinurad and febuxostat treatment were independent of blood pressure.
The effects of combined verinurad and febuxostat treatment were independent of blood pressure.
Improvements seen in glycemic, blood pressure, lipid control within the population partly explain decrease in albuminuria
The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.
Canagliflozin slows progression of kidney disease in participants with eGFR <30 mL/min/1.73 m2 with no increase in AKI
Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.
Whether successful treatment of depression reduces the risk for progression needs to be determined.
The NDA for finerenone is supported by data from the double-blind, placebo-controlled phase 3 FIDELIO-DKD trial.
The new KDIGO guideline highlights specific management differences by CKD severity.
Researchers assessed the risk for obstructive sleep apnea (OSA) among patients with type 2 diabetes and cardiovascular disease taking empagliflozin and further examined the effect of OSA on metabolic, cardiovascular, and renal outcomes.
Atrasentan outperformed both avosentan and bosentan for renoprotection in patients with type 2 diabetic kidney disease.